Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 28, 2016. The document serves as a transaction notification reporting dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share transactions executed by senior executives.
| Executive | Position | Transaction Type | Volume | Price (GBP) | Date |
|---|---|---|---|---|---|
| Sir Andrew Witty | CEO | Sale | 10,000 | 16.9350 | 2016-07-27 |
| Mr D S Redfern | Chief Strategy Officer | Option Exercise | 26,800 | 14.88 | 2016-07-27 |
| Mr D S Redfern | Chief Strategy Officer | Sale (Post-Exercise) | 26,800 | 16.942 | 2016-07-27 |
| Mr D S Redfern | Chief Strategy Officer | Option Exercise | 24,186 | 11.47 | 2016-07-27 |
| Mr D S Redfern | Chief Strategy Officer | Sale (Post-Exercise) | 24,186 | 16.938 | 2016-07-27 |
| Mr D S Redfern | Chief Strategy Officer | Option Exercise | 2,614 | 11.47 | 2016-07-28 |
| Mr D S Redfern | Chief Strategy Officer | Sale (Post-Exercise) | 2,614 | 17.035 | 2016-07-28 |
| Ms C Thomas | SVP, Human Resources | Sale | 43,000 | 16.9757 | 2016-07-28 |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. It reports routine insider trading activities, including the exercise of share options granted in 2007 and 2008 and subsequent sales on the London Stock Exchange.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. It is a statutory disclosure of executive share transactions.
Investor Verification Checklist
- Verify the total number of shares sold by executives versus shares acquired via option exercise to determine net insider selling.
- Confirm the exercise prices of the options (ranging from £11.47 to £14.88) against the market sale prices (approx. £16.93 to £17.03) to assess realized gains.
- Check subsequent filings to ensure these transactions were completed in accordance with the company's trading window policies.
- Note that this filing contains no operational or financial performance data; refer to the company's 20-F or interim reports for those metrics.